Trial of daunomycin in acute promyelocytic leukemia of childhood: a Southwest Oncology Group Study.
Children with acute promyelocytic leukemia were treated with aggressive daunomycin induction and 6-mercaptopurine and methotrexate maintenance. The remission rate was 8 out of 10 fully evaluable patients. Three are still alive up to 32 months. With vigorous induction therapy, occurrence of disseminated intravascular coagulation was rare. Only one case of DIC was seen in a child who had pseudomonas sepsis at time of diagnosis. Since current protocols are more aggressive, future chemotherapy include patients with acute promyelocytic leukemia.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003630:Daunorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004211:Disseminated Intravascular Coagulation / Q000139:chemically induced; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*
D003630:Daunorubicin